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Antisense oligodeoxynucleotides formulated in cream preparations are being examined in the clinic as topical
therapy for psoriasis. To produce their intended anti-inﬂammatory effects, these large anionic molecules must
penetrate the stratum corneum and reach the living epidermis and dermis. A topically applied phosphorothioate
antisense oligonucleotide targeted to intercellular adhesion molecule-1 recently was shown to modulate cytokine-
inducible target gene expression in engrafted human skin. In this study, we examined the route of entry into mouse
skin of ﬂuorochrome-tagged or naked second-generation 20-O-methoxyethyl-modiﬁed oligonucleotides that react
specifically with an antibody, using topical cream-based formulations. In hairless mouse skin, immunohistochem-
ical analysis and ﬂuorescence microscopy were unable to detect the presence of oligonucleotide in the epidermis
or dermis following topical application although immunostaining was associated with the stratum corneum and
ﬂuorescein isothiocyanate-labeled oligonucleotide was observed in hair follicles. Kinetic analysis of oligonucleo-
tide topically applied to hair-clipped BALB/c mouse skin showed early follicular localization, diffusion of oligonuc-
leotide from the mid-follicle, and subsequent dermal accumulation. Saline formulation resulted in oligonucleotide
remaining within the hair follicle. These results suggest that oligonucleotide penetration in skin involves a follicular
route and further, that topical oligonucleotide therapy may be particularly well suited for altering physiology within
the hair follicle and related structures.
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Local delivery of oligonucleotides to skin mediated by top-
ically applied creams containing penetration enhancers is of
interest for the therapy of inflammatory skin disease and
possibly certain types of skin cancer. Previous work showed
that topically applied oligonucleotide was associated with
living skin tissues, using both capillary gel electrophoresis
as well as immunohistochemical techniques (Mehta et al,
2000). Oligonucleotide accumulation in skin following top-
ical application has been evaluated by several groups, with
variable results apparently influenced by the chemical mod-
ifications incorporated into the sequence as well as the use
of psoriatic or normal skin (Regnier et al, 1998; Mehta et al,
2000; White et al, 2002). Despite the demonstration of top-
ical penetration into skin, the route of oligonucleotide trans-
port through skin is unknown. Further understanding of
this mechanism of transport would potentially aid in the
development of better methodologies for topical oligonuc-
leotide delivery.
To produce pharmacodynamic effects, oligonucleotides
must penetrate the stratum corneum and reach the under-
lying tissues. Penetration of relatively large molecular weight
molecules across intact stratum corneum is known to be
limited (Mrowietz, 1992; Schmook et al, 1993), suggesting
an inherent obstacle that must be overcome for oligo-
nucleotides. A number of strategies have been implement-
ed to achieve transdermal drug delivery (Zewert et al, 1995;
Banga and Prausnitz, 1998; Regnier et al, 1998; Brand and
Iversen, 2000; Mehta et al, 2000; Tezel et al, 2002). The
focus of these studies, however, has been to deliver drugs
systemically rather than locally, and little is understood re-
garding the transport of oligonucleotides through the skin
using these methodologies.
The specific goals of this study were: (1) to determine
whether stratum corneum was indeed a major barrier to
oligonucleotide transport through skin and (2) to determine
whether there was a demonstrable route of delivery to the
epidermis and dermis in normal skin. Therefore, we per-
formed kinetic analysis of oligonucleotide transport and
compared the immunohistochemical and fluorescent stain-
ing patterns of oligonucleotides in mouse skin following
topical application in cream preparations. Our results indi-
cate that topically applied oligonucleotides accumulate in
the hair follicle and, in the presence of vehicles with a lip-
ophilic component, traffic into the dermis.
Results
Lack of penetration of topically applied formulated an-
tisense oligonucleotides (ASO) in hairless mouse
skin We used two main techniques for visualizing ASO
distribution in skin after topical application. ISIS 13920 is a
Abbreviations: ASO, antisense oligonucleotides; FITC, fluorescein
isothiocyanate; IHC, immunohistochemistry
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20-O-methoxyethyl (20-MOE) ASO that is recognized by
the 2E1 monoclonal antibody, facilitating interpretation of
immunohistochemistry (IHC) staining patterns. ISIS 18073 is
a fluorescently labeled ASO and visualization of the fluo-
rescent probes is a direct readout of ASO localization. Both
these compounds are 20 mer 20-MOE ASO. Initial observa-
tions showed a difference in localization pattern of ASO in
topical formulations when applied to hairless SKH1 versus
BALB/c mice. To investigate this further, we topically ap-
plied 5% ASO cream to hairless mice and sacrificed the
mice at different time points. The skin was harvested and
ASO localization was studied either by IHC (Fig 1A) or flu-
orescence microscopy (Fig 1B). Topical administration of
cream containing 5% ASO to hairless mice skin for different
time points (0, 3, 24 h) resulted in no visible staining of either
the dermis or epidermis (Fig 1A). To confirm the IHC data by
another method of detection, we also applied fluorescein
isothiocyanate (FITC)-labeled ASO similarly formulated to
hairless mouse skin and again there was no visible staining
of the epidermis and dermis. Interestingly, we observed
ASO distribution in what appears to be hair follicles at about
3 h (Fig 1B). It is known that hairless mice have hair follicles
but they are not well developed and fully functional (Lauer
et al, 1997). At 24 h, however, there was no detectable dis-
tribution of ASO in the epidermis or dermis as determined
by these visualization techniques.
Topically applied formulated ASO accumulates in the
dermis of BALB/C mice in a time-dependent manner We
observed that if the above experiment was repeated in
BALB/C mice, the results were very different. Similar to
above, 100 mL of the topical cream formulation was applied
to hair-clipped BALB/c mouse skin for different periods of
time, and the skin was harvested and analyzed for ASO
distribution by IHC and fluorescence microscopy. We ob-
served intense staining of the dermis in these treatment
groups, suggesting that ASO trafficked through the stratum
corneum and distributed to the dermis. Following the above
observations, we studied the kinetics of localization of for-
mulated ASO through what we observed to be a follicular
pathway. Hair-clipped BALB/C mice were treated with the
ASO cream formulation for different periods of time (0 h, 30
min, 1, 3, 8, 24 h) and the skin was harvested for detection
by IHC. The data (Fig 2A) suggest that ASO distribute into
the skin in a time-dependent manner. At around 3 h, there
seems to be diffusion of ASO in the dermis and this accu-
mulation increases over a period of 24 h. Follicular distri-
bution seems to be present as early as 30 min. The data
with FITC-labeled ASO formulation (Fig 2B) are consistent
with these observations. Additionally, it may be noted that
there was an intense fluorescent signal in the dermis with
much less fluorescence associated with the epidermis
(Fig 2B). Hair follicles were defined by accumulation of
Figure 1
Topical antisense oligonucleotide (ASO) distribution after administration in cream to hairless mouse skin. (A) Immunohistochemical pho-
tomicrographs of ISIS 5% 13920 cream formulation applied onto hairless mouse skin at 0, 3, and 24 h. Pictures taken at  10 magnification under a
Zeiss Axiolab microscope (Carl Zeiss, Inc., Thornwood, New York). Scale bar¼ 20 mm. (B) Fluorescein isothiocyanate photomicrographs after topical
application of ISIS 5% 18073 cream formulation at 0, 3, and 24 h. Note the localization of ASO in what appears to be the hair follicles at 3 h. Pictures
taken at  40 magnification under a Zeiss Axiolab microscope. Three animals were evaluated for each group; the micrographs show a repre-
sentative section from one animal. Scale bar¼20 mm.
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FITC-ASO at 3 h, at a time when dermal penetration was not
yet apparent. Collectively, these data suggest that ASO may
access the dermis via a follicular pathway.
Topically applied formulated ASO and not simple saline
formulations accumulates in the dermis of BALB/c
mouse skin To study whether the formulation helped ASO
distribute into the dermis of BALB/C mice, we also topically
applied a simple saline formulation (5% ASO dissolved in
saline). Interestingly, whereas there seemed to be localization
of ASO in the hair follicles after 24 h, there was no accu-
mulation of ASO in the dermis when the saline formulation
was used (Fig 3). These data suggest that the penetration
enhancer in the cream formulation is required to support the
trafficking of the ASO from the hair follicle to the dermis.
Discussion
Recent research has shown that hair follicles and sebaceous
glands may contribute significantly to topical and transdermal
delivery (Lauer et al, 1995; Li and Hoffman, 1995a; Cotsarelis,
Figure 2
Topical antisense oligonucleotide distribution after administration in cream to hairy mouse skin. (A) Immunohistochemical photomicrographs
of ISIS 5% 13920 cream formulation applied onto hair-clipped BALB/c mouse skin at 0 h, 30 min, 1, 3, 8, and 24 h. Pictures taken at  20
magnification under a Zeiss Axiolab microscope. Scale bar¼ 20 mm. (B) Fluorescein isothiocyanate photomicrographs after topical application of ISIS 5
%18073 cream formulation onto hair-clipped BALB/c mouse skin at 0, 3, and 24 h. Pictures taken at  40 magnification under a Zeiss Axiolab
microscope. Three animals were evaluated for each group; the micrographs show a representative section from one animal. Scale bar¼20 mm.
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2002). The total surface area of orifices of the pilosibaceous
units occupies only about 0.1% of the total skin surface area,
raising doubts on the significance of this pathway for delivery.
Certain areas of skin with a high density of follicles, such as
the face and scalp, however, can have as much as 10% of
skin surface area. Secondly, even though hair follicle open-
ings occupy only a small portion of the human skin surface
area, they are invaginations of the epidermis, providing a
much greater actual area for potential absorption below the
skin surface (Lauer et al, 1995). It has also been suggested
that the epidermis offers much lower resistance to polar
drugs than the stratum corneum (Elias et al, 1981). Hence,
follicular delivery is gaining attention as a viable route of
transdermal/topical delivery.
In this study, we have attempted to understand the traf-
ficking of ASO in cream formulations across mouse skin. We
tested localization of ASO across the skin of both hairless
SKH1 mice and hairy BALB/c mice. We have observed that
ASO as formulated do not penetrate hairless mouse skin.
But, the results were dramatically different when the same
ASO cream was applied to hair-clipped BALB/C mouse
skin. The data from these experiments led to the hypothesis
that the hair follicle is a route of ASO trafficking into skin
following application of a topical formulation. These data
are in agreement with other papers that have shown that
large macromolecules could be delivered to the skin via hair
follicles (Li et al, 1993a; Lieb et al, 1997). We followed the
kinetics of ASO distribution in BALB/c mice and found that
this localization was time-dependent. Dermal distribution of
ASO was seen only with cream formulations, and not with
simple saline formulations.
Most of the publications to date have shown delivery of
large molecules to hair follicles via formulations such as
liposomes (Li et al, 1992, 1993a, b; Li and Hoffman, 1995a,
b). Our data show that ASO when formulated in lipophilic
cream can distribute into the dermis via hair follicles. It has
been suggested that sebum, which flows into the hair fol-
licle from the sebaceous duct, may necessitate a certain
degree of lipophilicity for compounds to enter the hair fol-
licles (Mezei and Gulasekharam, 1982). The cream formu-
lation is presumably imparting a degree of lipophilicity that
permits delivery of ASO through hair follicles into the de-
rmis. Data published by Lauer et al suggest that the stratum
corneum favors permeation of lipophilic compounds,
whereas hair follicles favor penetration of polar compounds
(Lauer et al, 1997). These data also indicate that both for-
mulation differences and the relative number and functional
integrity of the hair follicles play important roles in the traf-
ficking behavior of topically applied ASO.
It is clearly evident from our study that a vehicle/formu-
lation with the right hydrophilic/hydrophobic balance is re-
quired for effective transport of ASO within the skin. These
data suggest the potential of these formulations for both
localized drug delivery to hair follicles as well as to treat
disorders of the skin. Further work is required to understand
clearly the mechanism for enhanced ASO delivery with
cream formulations.
Materials and Methods
Oligonucleotide selection and formulation All oligonucleotides
used in these studies were second-generation chemistries con-
taining the 20-MOE sugar modification. ISIS 13920 (mol. wt. 7235
Da) was chosen as an IHC marker for these distribution studies
because it is easily recognized by a specific antibody as described
below. ISIS 18073 is a fluorescently labeled ASO that enables de-
tection by fluorescence microscopy. Synthesis and purification
were performed as previously described (Monia et al, 1992, 1993).
For oligonucleotides formulated in cream, the following com-
position was used in these studies: glyceryl monostearate (10%),
hydroxypropyl methylcellulose (0.5%), isopropyl myristate (10%),
methylparaben (0.5%), propylparaben (0.5%), polyoxyl-40-stea-
rate (15%), and water.
In vivo mouse dermal delivery
Animals Six to eight weeks old hairless SKH1 or BALB/C mice
(Charles River Laboratories, Wilmington, Massachusetts) were
used in these studies. All studies were conducted utilizing proto-
cols and methods approved by the Institutional Animal Care and
Figure 3
Antisense oligonucleotide (ASO) in saline is not localized in the dermis of hairy mouse skin. Immunohistochemical photomicrographs of ISIS
5% saline formulation applied onto hair-clipped BALB/c mouse skin. Cream-alone controls showed no staining. Pictures taken at  20 mag-
nification under a Zeiss Axiolab microscope. Three animals were evaluated for each group; the micrographs show a representative section from one
animal. Scale bar¼20 mm.
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Use Committee and were carried out in accordance with the Guide
for the Care and Use Committee of Laboratory Animals adopted
and promulgated by the US National Institutes of Health. All an-
imals were provided food and water ad libitum and kept on a 12 h
light/dark cycle.
Dermal application BALB/c mice were hair-clipped the day before
the experiment while avoiding cuts to the skin and cream was
applied to the clipped area 24 h later. Approximately 100 mL of 5%
ISIS 13920 or 18073 ASO containing cream was applied over an
area of approximately 12 cm2 on the dorsal surface of the skin. The
formulation was rubbed onto the skin to ensure uniform distribu-
tion. Immediately after the treatment period, application sites were
cleaned of residual cream with a mild surfactant (2% Tween 80 in
water). Three mice were killed by exsanguination per time point
and skin samples were collected. For saline formulations, 100 mL of
5% ASO containing saline solution was applied to the area and
rubbed into the skin.
Histological evaluation Skin samples were carefully washed with
2% Tween 20 in PBS to remove any excess cream and fixed in
10% neutral-buffered formalin for 24 h before transferring to 70%
ethanol for dehydration and storage. The tissues were embedded
in paraffin and sectioned at 4 mm for analysis. The sections were
deparaffinized in xylene and hydrated through graded alcohols for
oligodeoxynucleotide (ODN) immunostaining and hematoxylin and
eosin (H&E) stains. The affinity purified antibody used in this work,
2E1-B5 ((Butler et al, 1997), Berkeley Antibody Company, Berkeley,
California), is an IgG1 that recognizes a CG or TCG motif in phos-
phorothioate ODN. Endogenous peroxidase activity was quenched
with peroxidase blocking reagent (Dako Corporation, Carpenteria,
California) for 10 min; sections were rinsed with PBS and treated
with proteinase K (Dako) for 20 min. After blocking with normal
donkey serum (Jackson Laboratories, Westgrove, Pennsylvania),
sections were incubated for 1 h with 2E1 monoclonal antibody
diluted at 1:1000. After rinsing, the antibody was detected using
HRP-donkey anti-mouse IgG F(ab)02 diluted 1:100 (Jackson) for
1 h. DAB (3,30-diamino-benzidene, Dako) was used as a substrate.
The tissue sections were counterstained with hematoxylin, dehy-
drated, and mounted with coverslips. Serial sections of the tissues
were stained with H&E for routine histopathological analysis.
Tissue sections were blinded and ISIS 13920 immunostaining
was evaluated using a Zeiss Axiolab microscope (Carl Zeiss, Inc.)
with a Sony color video camera (Mikron Instruments, San Marcos,
California) at various magnifications up to  200.
ODN distribution by FITC staining An 8 mm punch skin biopsy
containing FITC-labeled ISIS 18073 was obtained and placed in a
labeled cryomold and covered with OCT (O.C.T. Compound VWR
Cat. #25608-930). The mold containing the biopsy was gently
submerged in a pre-chilled dewar flask containing liquid nitrogen/
dry ice slurry for approximately 1 min until OCT turned white and
opaque. Tissue was stored in a 701C freezer until sections were
cut. Tissue was allowed to come to a 201C temperature before
cutting in a Leica CM 3050 cryostat (Leica, Northvale, New Jersey)
at 5 mm. Sections were picked up on ‘‘þ ’’ superfrost slides and
allowed to air dry for 4 h. Sections were then fixed in 5% neutral-
buffered formalin for 5 min, rinsed in distilled water to remove for-
malin, and then mounted in aquamount for fluorescent visualization
using a Zeiss Axioskop Microscope (Carl Zeiss) with a FITC filter.
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